Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in virtual one-on-one investor meetings and a fireside chat presentation at the 13th Annual Wedbush PacGrow (Virtual) Healthcare Conference.
BURNABY, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in virtual one-on-one investor meetings and a fireside chat presentation at the 13th Annual Wedbush PacGrow (Virtual) Healthcare Conference.
| Fireside Chat Details: | |
| Date: | Wednesday, August 10, 2022 |
| Time: | 2:55-3:25 pm ET |
| Presenters: | Ian Mortimer, President and CEO |
| Sherry Aulin, CFO |
A webcast of the fireside chat will be available on the “Investors” section of Xenon’s website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
